A quality-improvement project increased recognition of potential adverse reactions across selected neonatal medicines, including lorazepam.
The team introduced bedside monitoring for six target drugs. The tool was used about 83% of the time, and 28 potential reactions were identified, more than before implementation. The investigators also compared a neonatal-specific causality score with the Naranjo approach.
More reports after introducing surveillance can reflect improved recognition rather than a true rise in harm. The total spanned several drugs and should not be assigned to lorazepam alone. Causality scoring also organizes evidence without proving a drug caused each neonatal change. The project was local and faced identification and workflow challenges. It supports systematic assessment and documentation, while leaving drug-specific risk rates and effectiveness of prevention measures unresolved. A patient-level conclusion still requires timing, competing illness, dose, and response.
Original analysis of the supplied journal article, identified as PMC6831056.